Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with a 25.6% year-over-year earnings growth forecast and strong pipeline advancements, despite concerns over its premium valuation.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.